Your browser is no longer supported. Please, upgrade your browser.
Settings
IMVT [NASD]
Immunovant, Inc.
Index- P/E- EPS (ttm)-1.17 Insider Own65.00% Shs Outstand98.29M Perf Week2.33%
Market Cap1.06B Forward P/E- EPS next Y-1.33 Insider Trans0.05% Shs Float40.10M Perf Month8.09%
Income-111.20M PEG- EPS next Q-0.28 Inst Own33.70% Short Float9.04% Perf Quarter-9.07%
Sales- P/S- EPS this Y20.30% Inst Trans0.19% Short Ratio3.52 Perf Half Y-40.21%
Book/sh3.72 P/B2.48 EPS next Y15.30% ROA-26.40% Target Price- Perf Year-77.93%
Cash/sh3.30 P/C2.79 EPS next 5Y- ROE-27.60% 52W Range6.68 - 53.75 Perf YTD-80.04%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-83.70% Beta-
Dividend %- Quick Ratio18.80 Sales past 5Y- Gross Margin- 52W Low31.14% ATR0.39
Employees68 Current Ratio18.80 Sales Q/Q- Oper. Margin- RSI (14)46.48 Volatility4.28% 4.43%
OptionableYes Debt/Eq0.00 EPS Q/Q17.80% Profit Margin- Rel Volume0.36 Prev Close9.22
ShortableYes LT Debt/Eq0.00 EarningsAug 09 BMO Payout- Avg Volume1.03M Price8.76
Recom2.40 SMA20-1.74% SMA502.46% SMA200-46.12% Volume352,809 Change-4.99%
Aug-03-21Downgrade Robert W. Baird Outperform → Neutral $20 → $10
Aug-02-21Downgrade Credit Suisse Neutral → Underperform $12 → $7
Jun-01-21Downgrade Stifel Buy → Hold $28 → $9
Jun-01-21Downgrade Guggenheim Buy → Neutral
Oct-28-20Initiated UBS Buy $61
Oct-12-20Initiated Guggenheim Buy $63
Oct-08-20Initiated Stifel Buy $46
Oct-02-20Initiated Credit Suisse Outperform $49
Aug-26-20Reiterated H.C. Wainwright Buy $34 → $40
Aug-25-20Initiated Raymond James Outperform $35
Jul-29-20Initiated H.C. Wainwright Buy $34
Feb-24-20Initiated SVB Leerink Outperform $24
Oct-11-21 04:15PM  
Sep-27-21 08:00AM  
Sep-15-21 07:00AM  
Sep-08-21 11:30AM  
08:00AM  
Aug-10-21 11:51AM  
Aug-09-21 06:30AM  
Aug-06-21 04:22PM  
Aug-03-21 03:49PM  
Aug-02-21 05:03PM  
02:56PM  
07:30AM  
Jul-13-21 01:22PM  
Jul-01-21 11:30AM  
Jun-28-21 08:03AM  
Jun-18-21 02:55AM  
Jun-02-21 12:05PM  
11:02AM  
Jun-01-21 07:31AM  
May-19-21 09:31AM  
May-14-21 11:34AM  
Apr-20-21 07:14PM  
12:45PM  
11:00AM  
08:15AM  
Apr-19-21 12:45PM  
11:00AM  
10:00AM  
09:37AM  
08:30AM  
12:40AM  
Apr-18-21 12:00PM  
Apr-16-21 09:19PM  
11:50AM  
11:00AM  
10:12AM  
Apr-15-21 01:50PM  
11:00AM  
11:00AM  
10:11AM  
Apr-14-21 10:10AM  
10:00AM  
08:00AM  
Apr-13-21 07:25PM  
03:23PM  
10:09AM  
10:00AM  
Apr-12-21 02:25PM  
01:00PM  
12:00PM  
11:00AM  
Apr-11-21 04:16PM  
Apr-09-21 04:12PM  
02:14PM  
01:30PM  
12:00PM  
Apr-08-21 01:10PM  
01:01PM  
Apr-07-21 05:34PM  
03:55PM  
01:00PM  
12:50PM  
11:17AM  
10:19AM  
Apr-06-21 03:45PM  
11:00AM  
10:18AM  
Apr-05-21 03:41PM  
01:00PM  
11:00AM  
10:17AM  
Apr-03-21 07:15AM  
Apr-02-21 11:58PM  
12:20PM  
11:24AM  
Apr-01-21 11:10PM  
05:18PM  
12:30PM  
10:13AM  
03:47AM  
Mar-31-21 02:20PM  
10:12AM  
02:45AM  
Mar-30-21 01:00PM  
11:00AM  
09:15AM  
08:00AM  
Mar-29-21 10:18PM  
09:53PM  
05:00PM  
12:15AM  
Mar-27-21 09:10PM  
Mar-26-21 12:30PM  
12:15PM  
10:07AM  
Mar-25-21 10:10PM  
03:03PM  
Mar-24-21 01:50PM  
02:35AM  
Mar-23-21 01:00PM  
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hughes Douglas J.DirectorAug 27Buy8.2418,247150,35558,447Aug 30 09:08 AM
MIGAUSKY GEORGE VDirectorAug 20Buy7.657,00053,55067,200Aug 20 06:14 PM
Pande AtulDirectorAug 13Buy7.985,00039,90045,200Aug 16 05:29 PM
Fromkin Andrew J.DirectorAug 10Buy7.905,50043,45045,700Aug 11 02:12 PM